Table 3.
| Published journal | Cases | BRAF | TMB | Previous treatment | Previous treatment response | nIT strategy | nIT response evaluation | AEs during nIT | Radical resection after nIT | ypTNM stage | Adjuvant therapy | Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OncoImmunology | 2 | Wild type | High | None | None | Nivolumab 3mg/kg,q2w; 6cycles | PR | Fatigue, grade 2 | Yes | ypT0N0M0 (pCR) | None | NED (>1 year after operation) |
| Wild type | High | FOLFOXIRI;4cycles | SD | Nivolumab 3mg/kg,q2w; 6cycles | CR | None | No | N/A | None | NED (1 year after nIT) | ||
| EJC | 1 | N/A | N/A | None | None | Ipilimumab 1mg/kg + Nivolumab 3mg/kg,q2w; 2cycles; Nivolumab3mg/kg,1cycle | CR | None | Yes | ypT0N0M0(pCR) | nivolumab 3mg/kg, q2w ,4 months | NED (6 months after operation) |
| EJSO | 2 | Wild type | N/A | None | None | Toripalimab 240mg +XELOX q3w;4cycles | PR | Nausea, grade 1 | Yes | ypT0N0M0(pCR) | None | NED |
| Wild type | N/A | XELOX | None | Sintilimab200mg,q3w; 5cycles + bevacizumab 500mg,q3w;4cycles | PR | None | Yes | ypT0N0M0(pCR) | None | NED | ||
| JNCCN | 3 | N/A | N/A | None | None | Pembrolizumab 200mg, q3w;11cycles | CR | Fatigue, grade 2 | No | N/A | None | NED (17 months after nIT) |
| Wild type | High | FOLFOX; 8cycles | SD | Nivolumab 3mg/kg + Ipilimumab 1mg/kg, q3w;7cycles | CR | Fatigue and rash,grade 1 | No | N/A | None | NED (12 months after nIT) | ||
| N/A | N/A | None | None | Pembrolizumab +FOLFOX;7cycles | PR | Rash, grade 1 | Yes | ypT0N0M0(pCR) | None | NED (10 months after nIT) | ||
| OncoImmunology | 4 | N/A | N/A | None | None | Pembrolizumab240mg +XELOX,q3w;2cycles | PR | N/A | Yes | ypT0N0M0(pCR) | N/A | N/A |
| Wild type | N/A | None | None | Pembrolizumab 200mg +Ipilimumab 50mg,q3w; 4cycles | CR | N/A | No | N/A | N/A | N/A | ||
| Wild type | N/A | None | None | Nivolumab 140mg,q3w; 12cycles | PR | N/A | Yes | ypT0N0M0(pCR) | N/A | N/A | ||
| Wild type | N/A | None | None | Pembrolizumab 200mg,q3w;4cycles | PR | N/A | Yes | TRG 2 (PR) | N/A | N/A |
LACRC, Locally advanced colorectal cancer; nIT, Neoadjuvant immunotherapy; nCRT, Neoadjuvant chemoradiotherapy; EJC, European Journal of Cancer; EJSO, European Journal of Surgical Oncology; JNCCN, Journal of the National Comprehensive Cancer Network; MRF, Mesorectal fascia; EMVI, Extramural vascular invasion; MMR, Mismatch repair gene; IHC, Immunohistochemistry; MSI, Microsatellite instability; NGS, Next generation sequencing; TMB, Tumor mutation burden; PR, Partial response; PD, Progressive disease; SD, Stable disease; pCR, Pathological complete response; cCR, Clinical complete response; NED, No Evidence of Disease; TRG, Tumor regression grade; AEs, Adverse effects; N/A, not available;+, Positive;−, Negative.